Back to top
more

Swedish Orphan Biovitrum (BIOVF)

(Delayed Data from OTC)

$25.76 USD

25.76
NA

0.00 (0.00%)

Updated May 3, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BIOVF

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Swedish Orphan Biovitrum falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 85 135 122 44 78
Receivables 544 575 441 460 451
Notes Receivable 0 0 0 0 0
Inventories 365 330 399 333 187
Other Current Assets 200 70 61 53 58
Total Current Assets 1,195 1,111 1,024 890 775
Net Property & Equipment 24 27 57 58 55
Investments & Advances 13 12 23 20 5
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 80 87 89 67 37
Intangibles 5,669 3,965 4,480 4,228 3,958
Deposits & Other Assets 0 0 0 0 0
Total Assets 6,981 5,202 5,674 5,263 4,831
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 97 124 65 62 72
Current Portion Long-Term Debt 831 574 206 438 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 495 521 579 428 322
Income Taxes Payable 7 2 5 56 30
Other Current Liabilities 357 238 153 142 174
Total Current Liabilities 1,801 1,472 1,022 1,138 607
Mortgages 0 0 0 0 0
Deferred Taxes/Income 630 376 420 378 394
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,071 294 1,023 1,105 1,708
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 270 411 474 406 296
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,787 2,574 2,968 3,060 3,039
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 18 17 20 18 17
Capital Surplus 1,561 1,012 1,160 1,070 1,026
Retained Earnings 1,703 1,565 1,534 1,142 769
Other Equity -88 35 -8 -28 -21
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 3,194 2,629 2,705 2,202 1,791
Total Liabilities & Shareholder's Equity 6,981 5,202 5,674 5,263 4,831
Total Common Equity 3,194 2,629 2,705 2,202 1,791
Shares Outstanding 295.10 295.10 295.10 299.90 NA
Book Value Per Share 10.82 8.91 9.17 7.34 -0.02

Fiscal Year End for Swedish Orphan Biovitrum falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents 51 85 63 75 19
Receivables 770 544 594 566 616
Notes Receivable 0 0 0 0 0
Inventories 343 365 363 387 350
Other Current Assets 0 200 0 0 0
Total Current Assets 1,163 1,195 1,020 1,028 985
Net Property & Equipment 25 24 24 29 26
Investments & Advances 19 13 15 12 13
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 79 80 75 81 83
Intangibles 5,875 5,669 5,857 6,049 4,048
Deposits & Other Assets 0 0 0 0 0
Total Assets 7,161 6,981 6,990 7,199 5,154
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable 0 0 0 0 0
Accounts Payable 64 97 98 89 60
Current Portion Long-Term Debt 721 831 301 1,001 567
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 0 495 0 0 0
Income Taxes Payable 0 7 0 0 0
Other Current Liabilities 845 357 854 642 767
Total Current Liabilities 1,644 1,801 1,265 1,747 1,407
Mortgages 0 0 0 0 0
Deferred Taxes/Income 662 630 691 715 367
Convertible Debt 0 0 0 0 0
Long-Term Debt 1,096 1,071 1,619 1,642 284
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 293 214 380 417
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 3,711 3,787 3,805 4,504 2,494
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 19 18 18 16 16
Capital Surplus 1,594 1,561 1,489 958 975
Retained Earnings 1,810 1,703 1,604 1,639 1,628
Other Equity 27 -88 74 82 41
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 3,450 3,194 3,185 2,696 2,660
Total Liabilities & Shareholder's Equity 7,161 6,981 6,990 7,199 5,154
Total Common Equity 3,450 3,194 3,185 2,696 2,660
Shares Outstanding NA 295.10 295.10 295.10 295.10
Book Value Per Share -0.03 10.82 10.79 9.13 9.02